Activity in the first quarter was strong for the group phamarceutique Sanofi-Aventis. Like all its competitors, the French group has benefited from the epidemic of influenza A, which boosted its sales activity of vaccines.

Sanofi-Aventis issued a net profit from growing 9.7% to 2.427 billion euros at constant exchange rates. It's better than expected. The consensus reached by Reuters stood at 2.28 rather billion. Reduced to an action, the net earnings from spring up 9.4% to 1.86 euro. Good performance also operational. Operating income rose 6.5% to 3.3 billion euros while sales reached 7.38 billion euros, up 3.9%.

So the vaccines business that has been the source of this performance fast cash now.This branch has indeed registered a 56% to 944 million euros, 413 million euros on sales of vaccines against H1N1.

Sanofi-Aventis confirmed its 2010 targets

The world number four from the pharmacy always think to do for all of fiscal 2010 to grow its earnings per share from continuing operations of between 2% and 5% at constant exchange rates, "unless major unexpected adverse events .

The group said in a statement that this forecast reflects the input of generic medicines market in 2009 and sales of H1N1 vaccines in the fourth quarter of 2009. They also include the expected impact of health reform in the United States.

ALSO READ:

"The laboratories are revolutionizing their R & D